MedTrace Logo

Liraglutide and Cardio-Metabolic Risk Markers

NCT01715428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2017-11-22

No results posted yet for this study

Summary

Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.

Conditions

  • Type-2 Diabetes

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Giuseppe Montalto, MD · University of Palermo, Italy

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715428 on ClinicalTrials.gov